Trusted Outcomes

Many potential clients and family members may ask, “Does your program work? Do you have any statistics on the benefits of treatment at Monte Nido?”

The goal of Monte Nido is to prepare each graduate with the tools necessary to continue the path to full recovery. We have been evaluating the short- and long-term benefits of our services for some years now and have published the only peer-reviewed decade-long post-graduate outcome study on residential eating disorder clients.


The vast majority of our clients demonstrated significant changes in symptoms and behaviors from admission to discharge—and maintained that improvement throughout the course of the study. Our clients also showed significant changes in many of the psychological features of eating disorders, including body dissatisfaction and drive for thinness, which are important factors that affect the risk of relapse.

The results of this 10-year study suggest that the progress made in residential care carries forward after clients leave our programs. Our treatment philosophy and post-discharge transitional programs provide clients with the ability to make choices that help them move toward a healthy life. We believe this is the best measure of our effectiveness.


  • The study included 156 clients, who had stayed at a Monte Nido treatment center for a minimum of 30 days.
  • 75% of our graduates were willing to participate in our outcome study. We believe this is a testament to the connection we develop with our clients.

Anorexia Nervosa

  • 89% of clients were classified as having a good or intermediate outcome at 4.6 years post-graduation on average.
  • Good outcome (41%) = both weight restoration and a return of menses
  • Intermediate outcome (48%) = either weight restoration or a return of menses
  • An impressive finding is the average BMI increased.

Bulimia Nervosa

  • 81% of clients were classified as having a good or intermediate outcome at 3.8 years post-graduation on average.
  • Good outcome (62%) = symptom-free
  • Intermediate outcome (19%) = 50% reduction of symptoms[JJ1]